Nasdaq

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and ...
Seeking Alpha

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (RCKT) (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for ...
Morningstar

Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman

NAPLES, Fla., Aug. 12, 2025 /PRNewswire/ -- MC Sciences, an emerging biotech developing first-in-class novel therapeutics backed by ROC Venture Group, proudly announces the appointment of Dr. Mikael ...
Morningstar

Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board ...

Former Chief Scientific Officer & President of R&D at Pfizer, Dr. Mikael Dolsten brings decades of R&D and strategic leadership experience in pharmaceutical medicine to guide Marengo's next phase of ...